Lichen Simplex Chronicus Itch: An Update

An Update on Advancements in the Treatment of Lichen Simplex Chronicus Itch

Acta Dermato-Venereologica

TAKE-HOME MESSAGE

• The authors review the epidemiology, clinical characteristics, and pathophysiology, for lichen simplex chronicus (LSC), as well as therapeutic options. LSC affects an estimated 12% of the general population. In addition to topical corticosteroids, other topical treatment options for LSC include menthol, pramoxine, doxepin, aspirin with dichloromethane, a mixture of ketamine–amitriptyline–lidocaine in a lipoderm base, acetaminophen, and Janus kinase inhibitors. If topical agents fail, other treatments with reported success include gabapentin, narrowband ultraviolet B, and transcutaneous electrical nerve stimulation. Agents under investigation include dupilumab and the IL-31 inhibitors nemolizumab and vixarelimab.
• More treatments for pruritic conditions are becoming available with healthcare providers' growing understanding of the pathogenesis of itch.

–  Katherine M. Stiff, MD

Abstract 

Lichen simplex chronicus is a form of chronic localized pruritus with a secondary dermatitis, and one of the most common types of chronic itch conditions, estimated to affect more than 10% of the general population. However, despite its prevalence and burden, there has been limited research into the pathogenesis and aetiology of lichen simplex chronicus, which, historically, made it a challenging condition to treat. In recent years, our understanding of this condition, along with that of pruritus and the itch-scratch cycle, has increased greatly, enabling a substantial increase in treatment options. In addition, there are several new promising treatments currently in development and trials. This article discusses the definition, epidemiology, clinical characteristics, pathophysiology, and current therapeutic options for lichen simplex chronicus, in order to highlight recent advancements in this field.

Acta Dermato-Venereologica

Lichen Simplex Chronicus Itch: An Update

Acta Derm Venereol 2022 Oct 19;102(xx)adv00796, T Ju, A Vander Does, N Mohsin, G Yosipovitch

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.